Background Postthrombotic syndrome (PTS) is a long‐term complication after deep vein
thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood …

Introduction Despite treatment of acute deep vein thrombosis (DVT) with low molecular
weight heparin and warfarin, up to 50% of patients develop post-thrombotic syndrome (PTS) …

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to
warfarin reduces the risk of post‐thrombotic syndrome (PTS) after deep vein thrombosis …

Introduction Post-thrombotic syndrome (PTS) is a chronic complication of deep vein
thrombosis (DVT) that affects 20% to 50% of DVT patients. Standard DVT treatment included …

Post-thrombotic syndrome (PTS) is a common complication of deepvein thrombosis (DVT).
Poor quality treatment with vitamin K antagonists (VKA) is a risk factor for PTS. We …

The incidence of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis
(DVT) treated with direct oral anticoagulants (DOACs) remains a matter of debate. Hence …

Background Post-thrombotic syndrome (PTS) is common in patients with deep vein
thrombosis (DVT). It is unclear if different types of anticoagulant therapies (eg vitamin K …

Background: The post‐thrombotic syndrome is a chronic, poorly understood complication of
deep venous thrombosis (DVT). Objectives: To evaluate predictors of the post‐thrombotic …

Introduction Post-thrombotic syndrome (PTS) is a burdensome long-term complication of
deep vein thrombosis (DVT). Recent studies have suggested that rivaroxaban may reduce …

Background: Postthrombotic syndrome (PTS) has a major impact on the quality of life after
deep venous thrombosis (DVT). From clinical practice and related trials, anticoagulants …